Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

Several other research analysts have also commented on CTSO. B. Riley reissued a buy rating and set a $3.00 price objective on shares of Cytosorbents in a report on Wednesday, May 15th. HC Wainwright reissued a neutral rating and set a $1.00 price objective on shares of Cytosorbents in a report on Tuesday, May 7th.

Cytosorbents Stock Down 4.2 %

CTSO stock opened at $1.15 on Monday. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $62.45 million, a PE ratio of -1.95 and a beta of 0.57. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $3.59. The stock has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $0.93.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The company had revenue of $9.79 million during the quarter, compared to analyst estimates of $9.78 million. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities analysts predict that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

Several hedge funds and other institutional investors have recently bought and sold shares of CTSO. Key Client Fiduciary Advisors LLC boosted its stake in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares in the last quarter. Raymond James & Associates purchased a new stake in Cytosorbents in the fourth quarter worth approximately $56,000. CM Management LLC boosted its stake in Cytosorbents by 98.8% in the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after buying an additional 410,000 shares in the last quarter. Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after buying an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after buying an additional 299,103 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.